^
    1m
    IMC-F106C-101: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors (clinicaltrials.gov)
    P1/2, N=410, Active, not recruiting, Immunocore Ltd | Recruiting --> Active, not recruiting | N=727 --> 410 | Trial completion date: Aug 2026 --> Dec 2027 | Trial primary completion date: Feb 2026 --> Oct 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Kimmtrak (tebentafusp-tebn) • brenetafusp (IMC-F106C)
    1m
    TK-6302-01: A study testing a new treatment called TK-6302 for the first time in people with advanced cancers that have a genetic marker called HLA-A02:01 and a tumour protein called PRAME. (2025-521603-46-00)
    P1, N=24, Not yet recruiting, T-Knife GmbH
    New P1 trial
    2ms
    PRAME Immunohistochemistry-Guided Slow Mohs Micrographic Surgery for the Treatment of Stage 0 to IIc Cutaneous Melanoma (clinicaltrials.gov)
    P=N/A, N=36, Recruiting, University of California, Davis | Withheld --> Recruiting
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    PRAME (Preferentially Expressed Antigen In Melanoma)
    2ms
    Shared PRAME epitopes are T-cell targets in NUT carcinoma. (PubMed, J Immunother Cancer)
    PRAME is highly and frequently expressed in NUT carcinoma, and the most common oncoprotein causing NUT carcinoma, BRD4::NUTM1, contributes to these high PRAME levels. PRAME epitopes presented by HLA class I are a previously unrecognized therapeutic vulnerability for NUT carcinoma that warrants clinical trials testing PRAME-targeted immunotherapies in this neglected patient population.
    Journal • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • NSD3 (Nuclear Receptor Binding SET Domain Protein 3) • PRAME (Preferentially Expressed Antigen In Melanoma) • BRD4 (Bromodomain Containing 4) • NUTM1 (NUT Midline Carcinoma Family Member 1) • BRD3 (Bromodomain Containing 3)
    |
    brenetafusp (IMC-F106C)
    4ms
    TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors (clinicaltrials.gov)
    P1, N=24, Recruiting, Neowise Biotechnology
    New P1 trial
    5ms
    TACTOPS: TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=37, Completed, Baylor College of Medicine | Trial completion date: May 2027 --> Jul 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    6ms
    Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CD33 (CD33 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    MultiTAA T cell therapy
    6ms
    First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms. (PubMed, Cancers (Basel))
    Patients enrolled in the phase 1 part of CD-TCR-001 displayed signs of potential clinical and biological activity of MDG1011 among the small number of patients studied. Advanced disease stage and rapid progression in the r/r AML patients limited clinical impact. The acceptable safety profile of MDG1011 merits further investigation of this TCR-T therapy, potentially in patients at an earlier stage of their disease and with lower tumor burden.
    P1 data • Journal • First-in-human
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    HLA-A*02:01
    |
    MDG1011
    7ms
    Study of IMC-P115C in Advanced PRAME-Positive Cancers (clinicaltrials.gov)
    P1, N=140, Recruiting, Immunocore Ltd
    New P1 trial
    7ms
    ACTengine® IMA203 Combined With mRNA-4203 (clinicaltrials.gov)
    P1, N=15, Recruiting, Immatics US, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • anzutresgene autoleucel (IMA203)
    7ms
    ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=375, Recruiting, Immatics US, Inc. | Phase classification: P1 --> P1/2 | Trial completion date: Dec 2028 --> Jun 2032
    Phase classification • Trial completion date
    |
    Opdivo (nivolumab) • IMA203CD8 • anzutresgene autoleucel (IMA203)
    7ms
    TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (clinicaltrials.gov)
    P2, N=12, Completed, Baylor College of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    MultiTAA T cell therapy